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Recently the importance of measuring in vivo action 
spectra for photodynamic therapy (PDT) with various 
photosensitizers was pointed out in this journal [1]. It 
was shown that the effect of PDT with zinc phthalo- 
cyanine tetrasulphonic a id (ZnPcS4) increases consid- 
erably when the wavelength of the activating light is 
increased from 680 to 692 nm. In this regard a further 
comparison with haematoporphyrin derivative/photofrin 
and other recently presented information about phthal- 
ocyanines may be useful. In particular we wish to point 
out in this note the possible relevance of the fluorescence 
excitation spectrum and the possibility to measure the 
in vivo absorption spectrum of a photosensitizer by 
reflection spectroscopy. 
Preclinical and clinical studies on PDT with hae- 
matoporphyrin derivative (HpD) and photofrin have 
mostly been performed with light of 630 nm wavelength. 
The use of this wavelength is not supported by the in 
vivo action spectrum. The action spectrum for in vitro 
cell killing by HpD-PDT has a peak close to 630 nm 
[2]. However, the in vivo action spectrum for HpD-PDT 
(determined from damage to rat ears) has peaks close 
to 500 and 625 nm [3]. These wavelengths are the same 
as the wavelengths where the fluorescence excitation 
spectrum has a maximum [4]. Farrell et al. [5] have 
studied the wavelength dependence of the threshold 
for PDT-induced damage to rat liver and also found 
a maximum at 625 nm. Recently Potter et al. [6] (and 
personal communication) measured the absorption spec- 
trum of photofrin in vivo in a mouse tumor by reflection 
spectroscopy and observed a maximum at 625 nm. Thus 
it appears that the in vivo PDT action spectrum, ab- 
sorption spectrum and fluorescence excitation spectrum 
using HpD/photofrin all have a maximum at 625 nm, 
which differs somewhat from the in vitro PDT action 
spectrum. The difference between 625 and 630 nm is 
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not large, but it should be noted that in clinical protocols 
the wavelength for PDT is often prescribed at 630 + 3 
nm. This means that 633 nm would in principle be 
acceptable. Since the in vivo HpD-PDT action spectrum 
has a relatively narrow peak [3], PDT at 633 nm has 
considerably less effect than at 625 nm. 
Results similar to those of Griffiths et al. [1] for 
ZnPcS4 have recently been reported for aluminium 
phthalocyanine disulphonic acid (AIPcS2) by Cubeddu 
et al. [7]. The in vivo absorption spectrum of A1PcS2 
peaked at 685 nm and a similar red shift was found 
for the PDT action spectrum. Incidentally, Cubeddu 
et al. [10] also measured the in vivo absorption spectrum 
of photofrin, which again showed a maximum at 625 
rim. 
The fluorescence excitation spectrum for ZnPcS4 in 
cells as reported by Griffiths et al. [1] has a broad 
maximum that does not correlate well with the PDT 
action spectrum. In view of the data on HpD/photofrin 
it should be worthwhile to measure both the in vivo 
fluorescence xcitation spectrum and the in vivo ab- 
sorption spectrum of ZnPcS, to see which, if any, 
corresponds best with the PDT action spectrum. An- 
other drug requiring such a study is zinc(II)-phthal- 
ocyanine in liposomes. This drug will soon be introduced 
for clinical PDT in a joint effort of Ciba-Geigy and 
Quadra Logic Technologies. Schieweck et al. [8] re- 
ported preclinical studies with this drug. Tumor necrosis 
required rather high light doses when PDT was per- 
formed with 671 nm light, the wavelength of maximum 
absorption in N-methyl-pyrrolidone. Van Leengoed et 
al. [9] excited liposomal zinc(II)-phthalocyanine with 
light of 675 nm wavelength and also needed rather 
high light doses (450 J cm-2) to achieve tumor necrosis. 
If liposomal ZnPc shows the same red shift in the in 
vivo action spectrum as reported for other phthalo- 
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cyanines [1,7], the concomitant reduction in the required 
light dose for PDT, if performed at the optimum 
wavelength, has considerable clinical significance. The 
PDT action spectrum and/or the fluorescence xcitation 
spectrum and the absorption spectrum of liposomal 
ZnPc should therefore be studied in vivo before this 
drug is tested clinically. Naturally this holds for any 
other new photosensitizer considered for clinical use. 
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